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The tumor necrosis factor-a (TNF-a) gene has been proposed as a major candidate gene in psoriatic arthritis (PsA).
TNF-a is a therapeutic target for patients responding poorly to conventional treatments. We investigated the role
of single-nucleotide polymorphisms (SNPs) at positions  238,  308, and þ 489 of the TNF-a gene in the genetic
susceptibility to PsA, in the severity of the disease, and, finally, in the response to TNF-a inhibitors (adalimumab,
etanercept, or infliximab). Fifty-seven Caucasian PsA patients and 155 healthy matched controls were studied. The
SNP þ 489 variant allele A was significantly associated with PsA susceptibility (P¼ 0.0136) and severity of clinical
(Psoriasis Area and Severity Index score, American College of Rheumatology criteria, Disease Activity Score 28,
and Disability Index Health Assessment Questionnaire) and laboratory (C-reactive protein and erythrocyte
sedimentation rate) parameters (P-values ranging from 0.016 to 2.908 10 12). The difference in severity was
accounted for by the differences between the AA and GA genotypes with respect to the GG genotype. The SNP
þ 489A allele shows a trend of association with the response to PsA treatment with etanercept. These findings
suggest a role of the SNP þ 489A allele in the susceptibility and severity of PsA.
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INTRODUCTION
Psoriatic arthritis (PsA) is a complex immune-mediated
disease that results from the interplay between multiple
genetic and environmental factors (Gladman and Rahman,
2001). Genetic factors may significantly contribute to the
etiology of the disease, which has a proved inheritability,
as reflected by an elevated relative risk (450%) among
first-degree relatives suffering from the disease (Moll and
Wright, 1973). It has been estimated that at least one-third
of the genetic contribution to PsA resides in the major
histocompatibility complex region (Bowcock and Cookson,
2004). The tumor necrosis factor-a (TNF-a) gene, which
is located in the short arm of chromosome 6 in the
major histocompatibility complex class III region between
the HLA-B and HLA-DR genes, has been proposed as a major
candidate gene in PsA (Kane and FitzGerald, 2004).
This hypothesis is supported by studies that have found high
serum, synovial fluid, and synovial membrane TNF-a levels in
patients with PsA (Partsch et al., 1997; Danning et al., 2000).
Indeed, TNF-a is presently a therapeutic target for patients
responding poorly to conventional disease-modifying
antirheumatic drugs (DMARDs). The observation that anti-
TNF-a biologic therapy retards or even stops the progression
of the anatomic damage has changed our views on the
inevitable relentless progression that was thought to occur
with DMARDs treatment. The discovery that anatomic
damage may be reduced indicates that early therapy with
biological drugs should be ideally adopted to achieve
clinical and radiological remission. Unfortunately, not all
patients respond to TNF-a inhibitors. The reasons for this
lack of response are unclear as yet, therefore there is a great
interest in this research area because the prediction of
response would prevent unnecessary therapy, rationalize
treatment costs, and represent a significant advance in
patient care.
Several single-nucleotide polymorphisms (SNPs) have been
identified in the TNF-a gene promoter (Hohler et al., 2002).
Previous studies have evaluated the potential role of the SNPs
 238,  308, and þ489 position in the first intron of the
TNF-a gene in the susceptibility to some rheumatic auto-
immune diseases such as rheumatoid arthritis (van Krugten
et al., 1999), systemic lupus erythematosus (Lin et al., 2009),
and systemic sclerosis (Tolusso et al., 2005). Collectively, they
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indicate that: (i) carriers of the SNP þ489A allele and of the
SNP 238G/G genotype have a decreased and an increased
risk, respectively, of developing severe rheumatoid arthritis in
the European population (van Krugten et al., 1999; Fabris
et al., 2002; Low et al., 2002); (ii) the SNP þ 489A allele may
contribute to systemic lupus erythematosus genetic suscepti-
bility in the Chinese population (Lin et al., 2009); (iii) the SNP
 238A/G and A/A genotypes and the SNP þ 489A/G
genotype are increased in Italian systemic sclerosis patients
(Tolusso et al., 2005).
Several population studies designed to evaluate the associa-
tion between some TNF-a gene polymorphisms, namely G to
A substitutions at positions 238 and  308, and PsA lead
to conflicting results. In fact, some authors found a strong
association between these TNF-a promoter polymorphisms
and PsA, suggesting that both polymorphisms could be used as
biomarkers to predict the risk of the disease (Ho¨hler et al.,
1997; Hamamoto et al., 2000; Hohler et al., 2002; Nishibu
et al., 2002; Balding et al., 2003; Mossner et al., 2005;
Rahman et al., 2006). In particular, Hohler et al. (2002)
reported a highly significant association of the SNP 238A
with PsA in the German population and Balding et al. (2003)
observed the association of the SNP 308 with PsA in Irish
patients. Moreover, Hamamoto et al. (2000) studied 20
Japanese patients suffering from PsA and demonstrated that
these patients have a genotype G/G at both  238 and  308
SNPs of the TNF-a gene. Finally, Rahman et al. (2006) carried
out a meta-analysis of all TNF-a association studies in White
PsA patients and confirmed that the SNP  238A variant was
a significant risk factor for this disease. By contrast, Gonzalez
et al. (2001, 2002) excluded the association between the SNPs
238 and 308 and PsA in the Jewish and Spanish popula-
tions. The discrepant results found among populations may be
the consequence of ethnic admixture causing population
stratification, of population-specific gene–gene or gene–
environment interactions, and of statistical fluctuations
(Ioannidis et al., 2001; Huizinga et al., 2004). Indeed,
Gonzalez et al. (2001, 2002) suggested that the reported
association between the SNPs –238 and –308 may only reflect
that both are in linkage disequilibrium with major histo-
compatibility complex class I chain–related gene A (MICA)-
A9 as they demonstrated that polymorphism MICA-A9 was
present at a higher frequency in Jewish and Spanish PsA
patients.
Previous studies examined whether the SNP 308 and
238 could influence the therapeutic response to TNF-a
inhibitors in patients with rheumatoid arthritis. In particular,
the SNP 308G/G genotype seems to favor a better response
to TNF-a inhibitors (Seitz et al., 2007), whereas the SNP
308A allele predicts poor response to these biological drugs
in this disease (O’Rielly et al., 2009). By contrast, it has been
reported that the SNP  238A/G genotype seems to be
associated with the response to infliximab (Lee et al., 2010).
The associations between TNF a gene polymorphisms and
response to anti-TNF therapy in patients with psoriasis and
PsA have been recently reviewed (Prieto-Pe´rez et al., 2013). In
particular, the polymorphism –857 (C allele) and rs1061622 in
TNFRSF1B (T allele) have been found to be associated with a
good response to etanercept, but not to infliximab or
adalimumab, in patients with psoriasis (Vasilopoulos and
Manolika, 2012).
However, to our present knowledge, studies on the associa-
tion of þ 489 polymorphism with PsA susceptibility and
response to TNF-a inhibitors are not reported in the literature.
In this study, we investigated the role of SNPs at positions
238, 308, and þ 489 within the TNF-a gene in PsA
susceptibility, severity, and response to TNF-a inhibitors.
RESULTS
Patients’ baseline characteristics
Baseline characteristics of patients indicate that the majority
of them were affected by type 2 psoriasis, by polyarticular
involvement, and by active disease as shown by the elevated
Disease Acitivity Score 28 (DAS28), Psoriasis Area and
Severity Index (PASI), physician’s global assessment of disease
activity, patient’s global assessment of disease activity,
patient’s visual analogic scale of pain, and Health Assessment
Questionnaire (HAQ) mean values, as well as by C-reactive
protein levels or erythrocyte sedimentation rates (Table 1).
Plain radiographs of hands and feet were obtained in 42
patients. Thirty-three of them (78.6%) had joint erosions of
hands and feet, and 13 (31%) had radiographic signs of
periostitis. Magnetic resonance imaging demonstrated sacroi-
liitis in eight (14%) and spondylitis in five (9%) patients.
Associations between TNF-a gene polymorphisms, PsA
susceptibility, and disease severity
There was no significant difference in the frequency of the
SNPs 308 and 238 genotypes between PsA patients and
controls. Conversely, the A allele of the SNP þ 489 was
significantly associated with PsA susceptibility (P¼0.0136)
(Table 2). The SNP þ489 genotype was also strongly
associated with disease severity as shown by its highly
significant association (Po10 7) with most clinical and
laboratory parameters and, although to a lesser degree, with
DAS28 (P¼0.01). In particular, the most significant asso-
ciations were those with HAQ and PASI (P¼2.911012
and P¼4.9 1012, respectively) (Table 3). The significance
of the associations was maintained for all parameters, but for
DAS28, after correcting for the number of tests performed.
These results were confirmed by analysis of variance as well
as by the nonparametric Kruskal–Wallis test (data not shown).
For each parameter analyzed, the difference in severity
was accounted for by the differences between the AA and
GA genotypes with respect to the GG genotype, whereas no
differences in severity could be detected between individuals
carrying the GA and the AA genotype. A representative
example concerning HAQ and PASI is shown in Figure 1.
Dichotomizing the number of swollen and tender joints, based
on the cutoff of minor or X5, yield to a similar association as
expected (data not shown). Finally, the SNP þ 489 A allele
was also significantly associated with the presence of joint
erosions, periostitis, sacroiliitis, and spondylitis (Table 4).
Collectively, these data support the role of the SNP þ 489 A
allele not only in disease susceptibility but also in disease
severity.
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Associations between TNF- a gene polymorphisms and response
to TNF-a inhibitors
Thirty out of 57 patients responded to the first TNF-a inhibitor
(17 to etanercept, 10 to infliximab, and 3 to adalimumab) and
19 out of 21 patients responded to the second TNF-a inhibitor
(9 to etanercept, 9 to adalimumab, and 1 to infliximab). The
difference in responsiveness to the different anti-TNF-a drugs
could be accounted for due to their pharmacology (mAb or
soluble receptor) as well as to acquired drug resistance or drug
level decrease related to the development of neutralizing
antibodies. Among the 49 responders to the first or second
TNF-a inhibitor, 15 achieved ACR70, 13 ACR50, and
21 ACR20 response after 3 months of therapy. Furthermore,
29 and 20 patients achieved ACR70 and ACR50 responses at
T6, respectively. An improvement of DAS28 value 41.2 was
achieved in 18 responder patients at T3 and in all responders
at T6. The mean DAS28 value fell in responder patients from
5.60±0.45 at T0 to 4.69±0.17 at T3 and to 3.24±0.22
at T6. The mean PASI score value decreased in responder
patients from 11.27±3.26 at T0 to 2.63±1.44 at T3.
The SNPs  308 and  238 genotype frequencies were not
significantly different between patients and controls (P¼ 0.739
for SNP 308 and P¼0.062 for SNP 238) and were
not significantly associated with the clinical outcome of PsA
patients after anti-TNF-a treatment (Supplementary Tables). As
far as the SNP þ489 genotype is concerned, 16 and 10
patients carrying the SNP þ489 GG and the SNP þ 489 GA
genotypes, respectively, responded to etanercept, whereas no
response was observed in patients carrying the SNP þ489AA
genotype (Table 5). The frequency of SNP þ 489 G allele was
slightly higher in patients responding to etanercept, although
the difference did not reach the statistical significance
(P¼ 0.079). However, under the recessive model for the
variant allele, a nominally significant association could be
detected (P¼ 0.021). Notably, the SNP þ489AA genotype
was detected in five patients responding to adalimumab (exact
Table 2. SNP þ 489 alleles in controls and patients
Alleles
G, N (%) A, N (%) MAF P-value1
Controls 267 (86) 43 (22) 0.139
Patients 86 (75) 28 (25) 0.246 0.0136
Abbreviations: MAF, minor allele frequency (namely the frequency of the
A allele); SNP, single-nucleotide polymorphism.
1Significance of w2-test with Yate’s correction for the allelic association
with the disease (case-control comparison) and Fisher test (two tailed)
P-value for the allelic association in the subgroup comparisons.
Table 1. Baseline characteristics of patients
Male/female 25 (44%)/32 (56%)*
Age 50±7**
Disease duration (years) 12±2
Psoriasis: type 1/type 2 11 (19%)/46 (81%)
Plaque psoriasis (nail involvement
no. 3—palmoplantar no. 3)
21 (37%)
Guttate psoriasis 15 (26%)
Inverse psoriasis (nail involvement no. 2) 15 (26%)
Pustular psoriasis (nail involvement
no. 2—palmoplantar no. 1)
6 (11%)
Oligoarticular (p5 joints) 20 (35%)
Polyarticular (45 joints) 37 (65%)
Swollen joint count 12±7
Tender joint count 16±9
Erythrocyte sedimentation rate (mm/1st h) 57±13
C-reactive protein (mg dl 1) 14±4
Disease Activity Score (DAS) 28 5.60±0.45
Psoriasis Area and Severity Index (PASI) score 11.27±3.26
Visual analog scale (VAS) of pain 48±9.26
Physician’s global assessment of disease activity
(PhGADA)
56±10.33
Patient’s global assessment of disease activity
(PGADA)
54±9.04
Disability Index Health Assessment Questionnaire
(HAQ)
2±0.74
Values are *number and percentage or **mean±SD.
Table 3. Associations between clinical and laboratory
parameters and SNP þ 489
SNP þ 489 genotype
Parameters GG (N¼ 34) GA (N¼18) AA (N¼ 5) P-value1
ESR 49.80±8.002 65.70±10.02 72.20±15.40 1.15108
CRP 10.90±1.80 18.10±3.90 17.40±4.00 1.12109
Swollen joint
count
7.20±4.00 18.40±5.60 20.20±4.60 3.27 10 11
Tender joint
count
10.20±6.60 24.20±6.50 25.00±3.90 2.84109
VAS 42.40±5.10 56.70±6.90 54.00±11.40 7.36108
PhGADA 49.90±5.20 63.90±9.90 66.00±11.40 2.68108
PGADA 48.20±4.90 62.50±6.50 63.00±7.60 1.53 10 10
HAQ 1.20±0.20 2.30±0.50 2.30±0.30 2.91 10 12
DAS28 5.60±0.50 6.10±1.00 6.20±0.90 0.01102
PASI 8.80±1.00 13.30±2.40 13.40±1.00 4.90 10 12
Abbreviations: CRP, C-reactive protein; DAS28, Disease Activity Score 28;
ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Question-
naire; PASI, Psoriasis Area and Severity Index; PGADA, patient’s global
assessment of disease activity; PhGADA, physician’s global assessment of
disease activity; SNP, single-nucleotide polymorphism; VAS, visual analog
scale.
1Significance of the association between the parameters and SNP þ489
genotype. Statistical analysis was performed by Wald test (based on
t-distribution) asymptotic two-tailed P-value (P-values in italics are those
significant after Bonferroni’s correction).
2Values are mean±SD.
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confidence interval of 47.8–100%) but not to etanercept or
infliximab.
DISCUSSION
The TNF-a gene has long been considered a major suscept-
ibility gene in immune-mediated diseases including PsA
(Bowcock and Cookson, 2004). However, several population
studies designed to evaluate the association between some
TNF-a gene polymorphisms, such as G to A substitutions at
positions  238 and 308, and PsA lead to conflicting results
(Ho¨hler et al., 1997; Hamamoto et al., 2000; Gonzalez et al.,
2001, 2002; Hohler et al., 2002; Nishibu et al., 2002; Balding
et al., 2003; Mossner et al., 2005; Rahman et al., 2006). In this
study, we investigated the role of SNPs at positions 238,
 308, and þ 489 within the TNF-a gene in PsA suscepti-
bility, severity, and response to TNF-a inhibitors.
We did not find significant associations between the SNPs
 308 and 238 and PsA in 57 genotyped Italian patients,
although there was a clear trend for association with the SNP
 238 G allele that was previously found to be associated
with an older age of onset of the disease (Balding et al., 2003).
Of note, we demonstrated the strong association between
the SNP þ 489 variant allele A in the first intron of the TNF-a
gene, whose frequency of 14% in the Italian population
(D’Alfonso and Momigliano Richiardi, 1996) overlaps the
distribution found in the Dutch (12%) (van Krugten et al.,
1999) and the British (15%) (Mullighan et al., 1997) popula-
tions, and both PsA susceptibility and severity. Indeed,
the presence and progression of joint erosions of the hands
and feet as well as the presence of periostitis, sacroiliitis,
and spondylitis were associated with the SNP þ 489 A allele.
Table 5. SNP þ 489 genotype counts and frequencies
among responder and non-responder patients treated
with TNF-a inhibitors
Etanercept Infliximab Adalimumab
SNP þ489
genotype
R,
N (%)
NR,
N (%)
R,
N (%)
NR,
N (%)
R,
N (%)
NR,
N (%)
AA 0 (0) 3 (27) 0 (0) 3 (15) 5 (38) 0 (0)
GA 10 (38) 3 (27) 3 (30) 6 (30) 4 (31) 2 (67)
GG 16 (62) 5 (46) 7 (70) 11 (55) 4 (31) 1 (33)
Total 26 11 10 20 13 3
Abbreviations: NR, non-responders; R, responders; SNP, single-nucleotide
polymorphism; TNF, tumor necrosis factor.
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Figure 1. Means and 95% confidence intervals for Health Assessment Questionnaire (left) and Psoriasis Area and Severity Index (right) stratified by single-
nucleotide polymorphism þ 489 genotypes. P-values obtained by the internal post hoc comparisons are shown. NS, not significant.
Table 4. SNP þ 489 alleles in patient subgroups
Alleles
Patient subgroups G, N (%) A, N (%) MAF P-values1
Joint erosions
Presence 39 (59) 27 (41) 0.409 4.23 10 7
Absence 47 (98) 1 (2) 0.021
Periostitis
Presence 10 (38) 16 (62) 0.615 3.48 10 6
Absence 56 (82) 12 (18) 0.136
Sacroiliitis
Presence 6 (37) 10 (63) 0.625 5.42 10 4
Absence 80 (82) 18 (18) 0.184
Spondylitis
Presence 3 (30) 7 (70) 0.700 1.96 10 3
Absence 83 (80) 21 (20) 0.202
Abbreviations: MAF, minor allele frequency (namely the frequency of the A
allele); SNP, single-nucleotide polymorphism.
1Significance of w2-test with Yate’s correction for the allelic association to
the disease (case–control comparison) and Fisher’s test (two tailed) P-value
for the allelic association in the subgroup comparisons.
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Mullighan et al. (1997) reported that the SNP þ 489 A allele
may be associated with increased TNF-a levels, suggesting
that a genetic predisposition to produce higher levels of TNF-a
is an important factor in the development of erosions.
Significantly increased levels of TNF-a have been found in
PsA serum, synovial fluid, and synovial membrane (Partsch
et al., 1997; Danning et al., 2000) and our study suggests that
the SNP þ489 A allele, directly or in association with other
polymorphisms, could influence the events that lead to the
development and progression of joint erosions.
TNF-a inhibitors have demonstrated efficacy in large,
randomized controlled clinical trials either as monotherapy
or in combination with DMARDs in the treatment of chronic
immune-mediated or inflammatory diseases (Taylor, 2003;
Chang and Girgis, 2007) and are effective in improving skin
and joint inflammation and in retarding joint erosion in PsA
patients (Chang and Girgis, 2007; Murdaca et al., 2009;
Murdaca et al., 2011, Murdaca et al., 2012). As far as the
potential influence of TNF-a gene polymorphisms in the
therapeutic response to TNF-a inhibitors in PsA patients is
concerned, Seitz et al. (2007) reported an association with the
SNP 308 G/G genotype. This result is in disagreement with
our present study, as we found that the SNPs 308 and
238 do not seem to influence the clinical outcome of PsA
patients treated with TNF-a inhibitors. However, the study by
Seitz et al. (2007) enrolled mainly rheumatoid arthritis patients
and a small number of PsA patients. Therefore, their findings
were driven by rheumatoid arthritis patients and did not
necessary reflect the real situation for PsA patients. More-
over, in the study by Seitz et al. (2007) data on the severity of
the disease at onset and clinical and radiological follow-up
data are lacking.
Of interest, using the recessive model for the variant allele,
we detected a nominally significant association between
the SNP þ489 G allele and the response to treatment
with etanercept, whereas the SNP þ489 A/A genotype
was associated with a response to adalimumab but not to
etanercept and infliximab.
In conclusion, our findings suggest that: (i) the SNP þ 489
variant allele A, alone or in association with other polymorph-
isms in the same region, could influence the genetic suscepti-
bility to PsA and the severity of the disease; (ii) the SNP þ 489
G allele may promote the response to etanercept; and (iii) the
SNP þ489 A allele may favor the response to adalimumab.
Further studies performed in a larger series of subjects are
needed to confirm current results obtained in a limited
number of patients and to evaluate other polymorphisms
and their interactions with environmental factors for their role
in PsA susceptibility and, hopefully, to predict the response to
a specific TNF-a inhibitor.
MATERIALS AND METHODS
Patients and treatment
Fifty-seven Caucasian unrelated patients with PsA (25 males and 32
females; age 50±7 years) and 155 unrelated healthy Caucasian
controls (68 males and 87 females; age 49±8 years) of Italian geo-
graphical origin were enrolled. No significant difference was found
between the basic characteristics of patients and controls. The study
was conducted in adherence to the Helsinki Guidelines, approved by
the local Hospital Ethics Committee and written informed consent
was obtained from each patient. Inclusion criteria were: age above 18
years, PsA diagnosed according to the CASPAR criteria (Taylor et al.,
2006), active disease poorly responsive to previous treatment with at
least two nonsteroidal anti-inflammatory drugs and one DMARD,
negative pregnancy test, and written informed consent. PsA was
classified according to the pattern of peripheral joint disease as
oligoarticular (p5 joints ever involved) or polyarticular (45 joints
ever involved). Plain radiographs of the hands and feet were obtained
and the distal interphalangeal, proximal interphalangeal (PIP), meta-
carpophalangeal, and carpal joints in the hand and the proximal
interphalangeal and metatarsophalangeal joints in the feet were
examined. The presence of erosions and periostitis was recorded.
Spinal involvement was defined as a history of inflammatory back pain
or imaging evidence of sacroiliitis or spondylitis. Psoriasis was classi-
fied as type 1 (onset at age o40 years) or type 2 (onset at age X40
years). The baseline characteristics of patients are reported in Table 1.
The patients eligible for anti-TNF-a therapy underwent a careful
medical history that included tuberculosis risk factors, such as birth or
residence in a region of high tuberculosis prevalence, previous
tuberculosis, or other risk factors that could facilitate tuberculosis
acquisition (i.e., corticosteroid treatment). Appropriate screening with
Mantoux test and a chest-X-ray were performed before starting
treatment and only negative patients were enrolled and treated.
Patients received infliximab infusions or subcutaneous injections of
adalimumab or etanercept as first-line treatment according to stan-
dard protocols. In particular, 29 received infliximab, 25 etanercept,
and 3 adalimumab. Patients who did not respond, as detailed below,
to the first TNF-a inhibitor at T3 were switched to another TNF-a
inhibitor. Among the eight patients who did not respond to etaner-
cept, three were switched to adalimumab and four to infliximab,
whereas one refused to switch to another TNF-a inhibitor. Among the
19 patients who did not respond to infliximab, 10 were switched to
etanercept and 4 to adalimumab, whereas 5 refused to switch to
another TNF-a inhibitor. All patients treated with infliximab also
received oral or intramuscular methotrexate (7.5–15 mg per week).
The PASI score, ACR criteria (ACR 20, 50, and 70), DAS28, and
HAQ were calculated at baseline (T0) and at 3 and 6 months (T3 and
T6, respectively) after starting treatment to evaluate the response to
TNF-a inhibitors. The patients were classified as ACR20 responders if
they had at least a 20% improvement in the number of swollen and
tender joints, as well as a 20% improvement in three of the following
five parameters: physician’s global assessment of disease activity,
patient’s global assessment of disease activity, visual analog scale of
pain, HAQ score, and C-reactive protein level or erythrocyte
sedimentation rate. The patients were classified as ACR50 and
ACR70 responders if they had at least a 50 and 70% improvement
according to ACR criteria. Furthermore, all patients enrolled had a
pretreatment DAS28 score 45.1 and, thus, responder patients were
those with a DAS28 improvement 40.6 (particularly, good respon-
ders and moderate responders were those with an improvement41.2
and 40.6–p1.2, respectively) and non-responders were those with
an improvementp0.6 or no improvement at all. The primary efficacy
end points were the proportion of patients with ACR20 response,
DAS28 improvement41.2, and a 75% reduction in the PASI score at
T3. Secondary end points were the proportion of patients with ACR50
and ACR70 at T3 and/or T6.
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Molecular analysis
Genomic DNA was extracted from peripheral blood samples accord-
ing to standard protocols (Miller et al., 1988). The polymorphisms of
SNPs  238 G4A (rs361525) and  308 G4A (rs1800629), located
in the promoter of TNF-a gene, and of SNP þ 489 G4A
(rs80267959), located in intron 1 of TNF-a gene, were selected for
investigation. The genomic region of TNF-a including these SNPs was
amplified by PCR. Detailed protocols and primer sequences are
available on request. The three polymorphisms were genotyped by
direct sequencing. Sequencing reactions were performed using
BigDye Terminator Sequencing Kit v3.1 (Applied Biosystems, Foster
City, CA), according to the manufacturer’s instructions, and resolved
on an ABI 3100—Avant automated sequencer (Applied Biosystems).
Hardy–Weinberg equilibrium was assessed in the sample series to
identify potential genotyping errors. No deviation from Hardy–
Weinberg expectation was found on both populations.
Statistical analysis
The hypothesis of genotypic and allelic associations between the
SNPs and the disease and between the SNPs and the response to drug
treatment were tested by Pearson’s w2-test with 1df and Yate’s
continuity correction or by Fisher’s exact test as appropriate. The
statistical significance level was set at a¼ 0.05. Associations between
SNPþ 489 genotypes and clinical parameters regarded as quantita-
tive traits were calculated by the Wald test implemented in PLINK
(Purcell et al., 2007). As the analysis has been performed for 10
clinical parameters and 3 SNPs, the Bonferroni’s correction has
been applied to the asymptotic P-values, setting a¼ 0.002 for the
level of significance. The differences between the means among the
genotypes have been confirmed by analysis of variance and post hoc
internal comparisons by the Kruskal–Wallis nonparametric test. The
clinical traits regarding the number of joints affected have
also been dichotomized as p5 and above 5, and the comparison
of allelic distributions among the two groups has been carried out by
Fisher’s exact test.
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